Anti-Hu CD34 FITC
Size: 100 tests
Reactivity: Non-human primates, Human
Excitation laser: blue (488 nm)
Store at: 2-8°C. Protect from prolonged exposure to light. Do not freeze.
CD34 for Stem Cells
CD34 is a cell surface glycoprotein that acts as a crucial stem cell marker, particularly for hematopoietic stem cells (HSCs) and endothelial progenitor cells. Its expression is associated with early progenitor cells and is commonly used to identify and isolate stem cells from bone marrow or peripheral blood samples.
FITC (Fluorescein isothiocyanate) is a fluorochrome that can be conjugated to antibodies, such as anti-CD34, allowing for the visualization and quantification of CD34+ cells. The combination of FITC with human anti-CD34 provides a powerful tool for identifying, isolating, and studying stem cells using flow cytometry.
Flow cytometry is a technique that allows for the rapid analysis of multiple characteristics of single cells as they flow in a liquid suspension through a laser beam. By conjugating FITC to anti-CD34 antibodies, researchers can specifically detect and quantify CD34-expressing cells in a sample.
In stem cell research, flow cytometry with FITC human anti-CD34 has several applications:
- Identification and Isolation: Using FITC human anti-CD34, researchers can identify and sort CD34+ stem cells from mixed cell populations, such as bone marrow aspirates or peripheral blood samples. This allows for the enrichment of a population of interest, which can then be used for further studies or therapeutic applications.
- Quantification: Flow cytometry can provide quantitative data on the percentage of cells expressing CD34 in a given sample. This is crucial for assessing the quality of stem cell preparations or monitoring changes in stem cell populations over time.
- Functional Studies: After isolating CD34+ cells, researchers can subject them to various in vitro conditions to study their differentiation potential, proliferation rates, and responses to specific stimuli.
The importance of CD34 as a stem cell marker cannot be overstated. Its presence indicates a population of cells with high regenerative potential, making them ideal candidates for therapeutic applications like bone marrow transplantation or regenerative medicine. CD34+ cells have the ability to differentiate into various blood cell lineages, making them invaluable for hematological studies and treatments.
In conclusion, the combination of FITC human anti-CD34 and flow cytometry offers a sophisticated and efficient method for stem cell researchers to identify, quantify, and study CD34-expressing cells. Understanding and harnessing the potential of CD34+ stem cells will continue to drive advancements in regenerative medicine, hematological research, and therapeutic applications.
EXBIO Praha A.S., Czech Republik